Theranostics in targeting fibroblast activation protein bearing cells : Progress and challenges
Copyright © 2023 Elsevier Inc. All rights reserved..
Cancer cells are surrounded by a complex and highly dynamic tumor microenvironment (TME). Cancer-associated fibroblasts (CAFs), a critical component of TME, contribute to cancer cell proliferation as well as metastatic spread. CAFs express a variety of biomarkers, which can be targeted for detection and therapy. Most importantly, CAFs express high levels of fibroblast activation protein (FAP) which contributes to progression of cancer, invasion, metastasis, migration, immunosuppression, and drug resistance. As a consequence, FAP is an attractive theranostic target. In this review, we discuss the latest advancement in targeting FAP in oncology using theranostic biomarkers and imaging modalities such as single-photon emission computed tomography (SPECT), positron emission tomography (PET), computed tomography (CT), fluorescence imaging, and magnetic resonance imaging (MRI).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:329 |
|---|---|
| Enthalten in: |
Life sciences - 329(2023) vom: 15. Sept., Seite 121970 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rezaei, Sahar [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
EC 3.4.21.- |
|---|
| Anmerkungen: |
Date Completed 14.08.2023 Date Revised 10.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.lfs.2023.121970 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359812856 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359812856 | ||
| 003 | DE-627 | ||
| 005 | 20240114233338.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.lfs.2023.121970 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1255.xml |
| 035 | |a (DE-627)NLM359812856 | ||
| 035 | |a (NLM)37481033 | ||
| 035 | |a (PII)S0024-3205(23)00605-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rezaei, Sahar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Theranostics in targeting fibroblast activation protein bearing cells |b Progress and challenges |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.08.2023 | ||
| 500 | |a Date Revised 10.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a Cancer cells are surrounded by a complex and highly dynamic tumor microenvironment (TME). Cancer-associated fibroblasts (CAFs), a critical component of TME, contribute to cancer cell proliferation as well as metastatic spread. CAFs express a variety of biomarkers, which can be targeted for detection and therapy. Most importantly, CAFs express high levels of fibroblast activation protein (FAP) which contributes to progression of cancer, invasion, metastasis, migration, immunosuppression, and drug resistance. As a consequence, FAP is an attractive theranostic target. In this review, we discuss the latest advancement in targeting FAP in oncology using theranostic biomarkers and imaging modalities such as single-photon emission computed tomography (SPECT), positron emission tomography (PET), computed tomography (CT), fluorescence imaging, and magnetic resonance imaging (MRI) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Fibroblast activation protein (FAP) | |
| 650 | 4 | |a Fluorescence | |
| 650 | 4 | |a Imaging | |
| 650 | 4 | |a PET | |
| 650 | 4 | |a SPECT | |
| 650 | 4 | |a Theranostic | |
| 650 | 7 | |a Serine Endopeptidases |2 NLM | |
| 650 | 7 | |a EC 3.4.21.- |2 NLM | |
| 650 | 7 | |a Membrane Proteins |2 NLM | |
| 700 | 1 | |a Gharapapagh, Esmaeil |e verfasserin |4 aut | |
| 700 | 1 | |a Dabiri, Shahram |e verfasserin |4 aut | |
| 700 | 1 | |a Heidari, Pedram |e verfasserin |4 aut | |
| 700 | 1 | |a Aghanejad, Ayuob |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Life sciences |d 1965 |g 329(2023) vom: 15. Sept., Seite 121970 |w (DE-627)NLM000007579 |x 1879-0631 |7 nnns |
| 773 | 1 | 8 | |g volume:329 |g year:2023 |g day:15 |g month:09 |g pages:121970 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.lfs.2023.121970 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 329 |j 2023 |b 15 |c 09 |h 121970 | ||